These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38908549)

  • 21. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
    Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
    Vuylsteke V; Chastain LM; Maggu GA; Brown C
    Drugs R D; 2015 Sep; 15(3):227-32. PubMed ID: 26254210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus.
    Artha IMJR; Bhargah A; Dharmawan NK; Pande UW; Triyana KA; Mahariski PA; Yuwono J; Bhargah V; Prabawa IPY; Manuaba IBAP; Rina IK
    Vasc Health Risk Manag; 2019; 15():149-157. PubMed ID: 31239693
    [No Abstract]   [Full Text] [Related]  

  • 25. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
    Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
    Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
    Kutoh E; Wada A; Murayama T; Takizawa Y
    Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
    Bays HE; Goldberg RB; Truitt KE; Jones MR
    Arch Intern Med; 2008 Oct; 168(18):1975-83. PubMed ID: 18852398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.
    Rondinelli M; Rossi A; Gandolfi A; Saponaro F; Bucciarelli L; Adda G; Molinari C; Montefusco L; Specchia C; Chiara Rossi M; Scardapane M; Arosio M; Genovese S
    Clin Ther; 2017 Jan; 39(1):159-169. PubMed ID: 27939305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Hagi K; Nitta M; Watada H; Kaku K; Ueki K
    J Diabetes Investig; 2023 Nov; 14(11):1246-1261. PubMed ID: 37610062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
    Furusawa S; Nomoto H; Oba-Yamamoto C; Takeuchi J; Ito M; Kurihara H; Aoki S; Miya A; Kameda H; Nakamura A; Atsumi T
    Endocr J; 2024 Jun; 71(6):603-616. PubMed ID: 38658349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
    Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
    Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycemic control and diabetic dyslipidemia in adolescents with type 2 diabetes.
    Le PT; Huisingh CE; Ashraf AP
    Endocr Pract; 2013; 19(6):972-9. PubMed ID: 23807519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
    Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
    Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes Self-Management Education and Medical Nutrition Therapy: A Multisite Study Documenting the Efficacy of Registered Dietitian Nutritionist Interventions in the Management of Glycemic Control and Diabetic Dyslipidemia through Retrospective Chart Review.
    Marincic PZ; Salazar MV; Hardin A; Scott S; Fan SX; Gaillard PR; Wyatt C; Watson L; Green P; Glover P; Hand M
    J Acad Nutr Diet; 2019 Mar; 119(3):449-463. PubMed ID: 30219311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Imeglimin for Type 2 Diabetes in Patients Undergoing Dialysis.
    Mima A
    In Vivo; 2023; 37(3):1334-1338. PubMed ID: 37103109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
    Ishibashi R; Hirayama K; Watanabe S; Okano K; Kuroda Y; Baba Y; Kanayama T; Ito C; Kasahara K; Aiba S; Iga R; Ohtani R; Inaba Y; Koshizaka M; Maezawa Y; Yokote K
    J Diabetes Investig; 2023 Dec; 14(12):1419-1422. PubMed ID: 37715448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.